03803nam a22004695i 4500001001800000003000900018005001700027007001500044008004100059020001800100024003500118050001400153072001500167072001500182072002300197072001800220100007400238245010900312250001800421264008200439300006500521336002600586337002600612338003600638347002400674505051400698520165301212650003102865650002402896650002302920650003102943650002102974650002502995650002903020700007003049710003403119773002603153776003603179776003603215776003603251856004603287978-981-97-1471-1DE-He21320251030111821.0cr nn 008mamaa240416s2024    si |    s    |||| 0|eng d  a97898197147117 a10.1007/978-981-97-1471-12doi 4aHC411-495 7aKC2bicssc 7a1F2bicssc 7aBUS0350002bisacsh 7aKCx1F2thema1 aAgten, Sven.eauthor.4aut4http://id.loc.gov/vocabulary/relators/aut10aBiopharma in Chinah[electronic resource] :bInnovation, Trends and Dealmaking /cby Sven Agten, Ben Wu.  a1st ed. 2024. 1aSingapore :bSpringer Nature Singapore :bImprint: Palgrave Macmillan,c2024.  aVII, 155 p. 35 illus., 34 illus. in color.bonline resource.  atextbtxt2rdacontent  acomputerbc2rdamedia  aonline resourcebcr2rdacarrier  atext filebPDF2rda0 aChapter 1: The Chinese healthcare and pharmaceutical market: Ignore at your own peril -- Chapter 2: China regulatory and legal reforms: Gateway to innovation and global integration -- Chapter 3: The golden age of the Chinese biopharma: Explosive growth in a thriving ecosystem -- Chapter 4: Innovation in the Chinese biopharma: From me-too to First-in-class -- Chapter 5: The art of the biopharma deal: The China angle -- Chapter 6: End if the first cycle. A drastic rest, future challenges and opportunities.  aThis book provides an insider’s overview of the emerging Chinese biopharma sector, its dynamics and trends, first bust and boom cycle, long-term perspectives, and how as a foreign company or investor to tap into this. China has gone from a country with no innovation in drug discovery, to a country which starts to out-license its biopharma technology to the rest of the world. The Chinese biopharma sector is only a decade old, but it already has become a new driver of growth and value. The book takes a closer look at what drives Chinese innovation in the biopharma sector, how to deal with this innovation, and what opportunities and challenges this provides for foreign companies. The book also takes a deep dive into its first biopharma boom and bust cycle, and what it means for the sector. It also explains what deals Chinese biopharma companies and investors are looking for, what works and what doesn’t, and how as a foreign company can tap into the world’s second largest healthcare market. Ben Wu has close to 30 years of experience in the pharmaceutical industry, holding senior executive positions in the Asia Pacific region for multinationals like J&J and Sanofi. He was active in several China originated biopharma companies, and is the founding CEO of Citrine Medicine, a venture capital backed biopharma. Originally from Belgium, Sven Agten has been living and working in China since 2004. He is a seasoned business executive working for SMEs and multinationals, with in-depth experience about business in China. He has published several books about China, all related to China business challenges, trends and opportunities. 0aAsiaxEconomic conditions. 0aMedicinexResearch. 0aBiologyxResearch. 0aTechnological innovations.14aAsian Economics.24aBiomedical Research.24aEconomics of Innovation.1 aWu, Ben.eauthor.4aut4http://id.loc.gov/vocabulary/relators/aut2 aSpringerLink (Online service)0 tSpringer Nature eBook08iPrinted edition:z978981971470408iPrinted edition:z978981971472808iPrinted edition:z978981971473540uhttps://doi.org/10.1007/978-981-97-1471-1